All In Biotech

Drug Trial Radar · NCT03740529

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

803

Actual

Start

Mar 15, 2019

Primary completion

Jan 27, 2025

Study completion Dec 23, 2025

Sponsor

Lead sponsor
Loxo Oncology, Inc.Eli Lilly (LLY)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Nov 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

Conditions

  • Chronic Lymphocytic Leukemia
  • Waldenstrom Macroglobulinemia
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • B-cell Lymphoma
  • Small Lymphocytic Lymphoma

Interventions

  • PirtobrutinibDrug

    Oral

  • VenetoclaxDrug

    Oral

  • RituximabDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: Up to 24 Months
  2. Recommended dose for further studyTime frame: Up to 24 Months
  3. To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC).Time frame: Up to 24 months
  4. To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0Time frame: Up to 24 Months
  5. To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0Time frame: Up to 24 Months

Locations

56 sites in 10 countries. Site status is shown where the registry gives one.

  • Mayo Clinic of Scottsdale

    Scottsdale, Arizona

  • Scripps Coastal Medical Center

    San Diego, California

  • University of California San Francisco, Medical Center at Paranassus

    San Francisco, California

  • Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut

  • Mayo Clinic-Jacksonville

    Jacksonville, Florida

  • Florida Cancer Specialists ORLANDO/DDU

    Lake Mary, Florida

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • Emory Clinic

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Northwell Health

    New Hyde Park, New York

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Durham VA Medical Center

    Durham, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Ohio State University Hospital

    Columbus, Ohio

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee

  • Mary Crowley Cancer Research Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Swedish Medical Center

    Seattle, Washington

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu

    Nantes, France

  • IRCCS - AOU di Bologna

    Bologna, Italy

  • IRCCS Ospedale San Raffaele

    Milan, Italy

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan

  • Kyoto Furitsu Medical University Hospital

    Kyoto, Japan

  • Okayama University Hospital

    Okayama, Japan

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.